Refine
Year of publication
Document Type
- Preprint (786)
- Article (647)
- Conference Proceeding (4)
- Doctoral Thesis (1)
- Working Paper (1)
Language
- English (1432)
- German (6)
- Multiple languages (1)
Has Fulltext
- yes (1439)
Is part of the Bibliography
- no (1439)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- BESIII (10)
- e +-e − Experiments (10)
- LHC (9)
- Branching fraction (7)
- Particle and Resonance Production (7)
- Heavy-ion collision (6)
- HIV (5)
- ALICE experiment (4)
- Charm Physics (4)
- Charm physics (4)
- Collective Flow (4)
- Electroweak interaction (4)
- Inverse kinematics (4)
- Jets (4)
- Lepton colliders (4)
- Quark-Gluon Plasma (4)
- Quasi-free scattering (4)
- Spectroscopy (4)
- ALICE (3)
- Biomarkers (3)
- COVID-19 (3)
- Charmed mesons (3)
- Experimental nuclear physics (3)
- Experimental particle physics (3)
- Hadronic decays (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- Oncology (3)
- Osteoporosis (3)
- Particle and resonance production (3)
- QCD (3)
- Quarkonium (3)
- Spectroscopic factors (3)
- breast cancer (3)
- e+-e− Experiments (3)
- pp collisions (3)
- Antiretroviral therapy (2)
- Beauty production (2)
- Bone density (2)
- Branching fractions (2)
- CT (2)
- Cirrhosis (2)
- Diagnostic markers (2)
- Diagnostik (2)
- Electroweak Interaction (2)
- Epilepsy (2)
- Exotics (2)
- Früherkennung (2)
- Heart failure (2)
- Heavy Quark Production (2)
- Hypertension (2)
- Inflammation (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Leptonic, semileptonic & radiative decays (2)
- Liver diseases (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Nuclear reactions (2)
- Particle Correlations and Fluctuations (2)
- Particle correlations and fluctuations (2)
- Particle decays (2)
- Pb–Pb collisions (2)
- Relativistic heavy-ion collisions (2)
- Richtlinie (2)
- Seizure (2)
- Shell model (2)
- Single electrons (2)
- Single-particle states (2)
- Spine (2)
- biomarker (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- pelvic packing (2)
- reference values (2)
- screening (2)
- 900 GeV (1)
- ABC transporters (1)
- ALICE detector (1)
- ALK (1)
- APRI (1)
- ATPases (1)
- Accelerators & Beams (1)
- Accelerators & storage rings (1)
- Acute coronary syndrome (1)
- Alpha-synuclein (1)
- Angiography (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Antiviral therapy (1)
- Aortic valve (1)
- Apoptosis (1)
- Artesunate (1)
- Atherosclerosis (1)
- Atomic & molecular beams (1)
- Atomic, Molecular & Optical (1)
- Atrial fibrillation (1)
- B cell receptor (1)
- B cell subpopulations (1)
- BESIII detector (1)
- BRCA1 (1)
- BRCA2 (1)
- Bacterial genomics (1)
- Bayesian inference (1)
- Beam loss (1)
- Bhabha (1)
- Biomarker (1)
- Bipolar disorder (1)
- Bleeding (1)
- Blood plasma (1)
- Blood pressure (1)
- Body mass index (1)
- Bone diseases, Metabolic (1)
- Boosted Jets (1)
- Born cross section measurement (1)
- Breast cancer (1)
- C-clamp (1)
- C3M (1)
- C4M (1)
- CD16 (1)
- CD56 (1)
- COVID 19 (1)
- CP violation (1)
- CRPC (1)
- CT dual-energy computed tomography (1)
- CVID (1)
- Cancer (1)
- Cancer treatment (1)
- Cardiac implantable electronic devices (1)
- Cardiac rehabilitation (1)
- Cardiac resynchronization therapy (1)
- Cardiac troponin (1)
- Cardiology (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell-to-Cell Spread (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Charmonium (1)
- Charmonium (-like) (1)
- Chemoradiotherapy (1)
- Child (1)
- Children (1)
- Chronic obstructive pulmonary disease (1)
- Circular accelerators (1)
- Clinical study (1)
- Clinical variation (1)
- Cohort studies (1)
- Collective Flow, (1)
- Comparative effectiveness research (1)
- Comparison with QCD (1)
- Complex II (1)
- Computed tomography, X-ray (1)
- Consensus (1)
- Consensus document (1)
- Contrast agent (1)
- Costs (1)
- Cross section (1)
- Cross sections (1)
- Culture positive (1)
- D meson (1)
- Dark photon (1)
- Dark sector (1)
- De-isolation (1)
- Death rates (1)
- Dermatomyositis (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Digestive system procedures (1)
- Direct nuclear reactions (1)
- Direct reactions (1)
- Docetaxel (1)
- Drug screens (1)
- Dual-energy computed tomography (1)
- Economics (1)
- Eicosanoids (1)
- Ejection fraction (1)
- Elderly (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Elliptic flow (1)
- Endocrinology (1)
- Endoscopy (1)
- Ephrin-B2–EphB4 (1)
- Esophagectomy (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus (1)
- Exercise training (1)
- Exosomes (1)
- FAPI PET (1)
- FIB-4 (1)
- FOS: Physical sciences (1)
- Falciparum (1)
- Fatty acids (1)
- Fatty liver (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Fibrosis (1)
- Fibrotest (1)
- First-line combination antiretroviral therapy (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Form factors (1)
- Forschung (1)
- Frailty (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- General practitioners (1)
- Genetics (1)
- German PID-NET registry (1)
- Gleason Grade Group (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HER2-positive (1)
- HIV-1 (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Health economics (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion storage ring (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hematology (1)
- Hepatitis B virus (1)
- Hepatitis C virus (1)
- Hepatocellular carcinoma (1)
- Hepatotoxicity (1)
- Hereditary breast and ovarian cancer (1)
- Herniated disk (1)
- High Energy Physics - Experiment (hep-ex) (1)
- High-energy neutron detection (1)
- Human behaviour (1)
- Hyperons (1)
- ICL (1)
- ICL V4c (1)
- INR (1)
- IgG substitution therapy (1)
- Image processing (1)
- Implantable cardioverter-defibrillator (1)
- In-TIPS thrombosis (1)
- Inclusive branching fraction (1)
- Inclusive spectra (1)
- Initial state radiation (1)
- Intensity interferometry (1)
- International normalized ratio (1)
- Intervertebral disc displacement (1)
- Invariant Mass Distribution (1)
- Invisible decays (1)
- Ionisation energy loss (1)
- Isoscalar giant resonances (1)
- Jet Physics (1)
- Jet Substructure (1)
- K0S (1)
- Kidney diseases (1)
- Lehre (1)
- Leukemias (1)
- Liver (1)
- Liver enzymes (1)
- Liver fibrosis (1)
- Liver transplantation (1)
- Long non-coding RNAs (1)
- Low & intermediate-energy accelerators (1)
- MHC (1)
- MRI (1)
- MTOR inhibitor (1)
- MYCN amplification (1)
- Malaria (1)
- Masquelet technique (1)
- Material budget (1)
- MicroRNAs (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitochondria (1)
- Molecular diagnostic testing (1)
- Molecular neuroscience (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-neutron detection (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multivariate analysis (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myocardial infarction (1)
- Myopia (1)
- NK cells (1)
- NMR spectroscopy (1)
- Nanoscale biophysics (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant therapy (1)
- Neural network (1)
- Neutrinos (1)
- Non-small cell lung cancer (1)
- Noninferiority (1)
- Nontuberculous mycobacteria (1)
- Nuclear astrophysics (1)
- Nuclear modification factor (1)
- Nuclear physics of explosive environments (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- ORL (1)
- Oesophagogastric cancer oxaliplatin (1)
- Oldest-old (1)
- One-nucleon removal (1)
- Open pulmonary tuberculosis (1)
- Opportunistic infections (1)
- Optical tweezers (1)
- Orbital electron capture (1)
- Osteoporotic fractures (1)
- Otorhinolaryngology (1)
- Oxidative phosphorylation (1)
- PDE‐5‐inhibitor (1)
- PID prevalence (1)
- PYTHIA (1)
- Pacemaker (1)
- Parkinson’s disease (1)
- Particle phenomena (1)
- Pathological complete response (1)
- Pb–Pb (1)
- Percutaneous (1)
- Personalized medicine (1)
- Phakic (1)
- Phantoms (imaging) (1)
- Phospholipids (1)
- Photon counting (1)
- Physical activity (1)
- Plasmodium (1)
- Plastic scintillator array (1)
- Point-of-care testing (1)
- Polarization (1)
- Pre-treatment drug resistance mutations (1)
- Predictive markers (1)
- Prevention (1)
- Production Cross Section (1)
- Prognosis (1)
- Properties of Hadrons (1)
- Protease inhibitor therapy (1)
- Proton (1)
- Proton–proton (1)
- Psychiatric disorders (1)
- QGP (1)
- Quantitative Imaging (1)
- Quantum chromodynamics (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quinine (1)
- RAS pathway (1)
- Radiative capture (1)
- Radiative decay (1)
- Rapidity Range (1)
- Rare decays (1)
- Reactions with relativistic radioactive beams (1)
- Registries (1)
- Regulatory networks (1)
- Relativistic heavy ion physics (1)
- Renal lesions (1)
- Research (1)
- Residency (1)
- Resolution Parameter (1)
- Respiratory infections (1)
- Retinal diseases (1)
- Rhabdomyoma (1)
- SARS CoV 2 (1)
- SARS-CoV-2 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SR-BI (1)
- SVR (1)
- Semi-leptonic decays (1)
- Severe malaria (1)
- Single muons (1)
- Single particle decay spectroscopy (1)
- Sociodemographic characteristics (1)
- Specialist training (1)
- Spectroscopic factors & electromagnetic moments (1)
- Sphingolipids (1)
- Sputum smear-negative (1)
- Stentoplasty (1)
- Storage ring (1)
- Subependymal giant cell astrocytoma (1)
- Super-resolution microscopy (1)
- Surgical oncology (1)
- Systematic Uncertainty (1)
- TB-therapy (1)
- TIPS (1)
- TR (1)
- TSC (1)
- Teaching (1)
- Techniques Electromagnetic calorimeters (1)
- Time Projection Chamber (1)
- Tomography (1)
- Tomography (x-ray computed) (1)
- Tracking (1)
- Transferases (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Transjugular Intrahepatic Portosystemic Shunt (1)
- Transverse momentum (1)
- Trigger (1)
- Triple negative (1)
- Triple-negative breast cancer (1)
- Two body weak decay (1)
- Type 2 diabetes (1)
- University hospitals (1)
- Universitätskliniken (1)
- Vector Boson Production (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Viral load (1)
- Virological failure (1)
- Virtual noncalcium reconstructions (1)
- Weiterbildung (1)
- X-ray computed (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- Y states (1)
- accessory proteins (1)
- acoustic radiation force impulse imaging (1)
- acute myeloid leukemia (1)
- adaptive immunity (1)
- adult and elderly patients (1)
- allogeneic transplantation (1)
- angiography (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- annual bleeding rate (1)
- anterior chamber depth changes (1)
- antigen presentation (1)
- auditory system (1)
- autoimmunity (1)
- biopsy cores (1)
- bone marrow derived mononuclear cells (1)
- cART (1)
- cancer therapy (1)
- cardiac magnetic resonance (1)
- castration resistance (1)
- cataract surgery (1)
- cell-free protein synthesis (1)
- center-of-mass energy (1)
- charmonium-like states (1)
- children (1)
- chronic kidney disease (1)
- clinical stage (1)
- co-infection (1)
- cohlear implant (1)
- cohort study (1)
- collagen degradation marker (1)
- component study (1)
- computer-assisted (1)
- critical size defect (1)
- cryo-EM (1)
- cyanines (1)
- cytarabine dose (1)
- dE/dx (1)
- decision aids (1)
- detector (1)
- dimuon (1)
- dislocation (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- e-scooter (1)
- effective lens position (1)
- effectiveness (1)
- elderly (1)
- electric and acustic stymulation (1)
- electric scooter (1)
- electron-positron collision (1)
- embolization (1)
- erectile dysfunction (1)
- experimental results (1)
- exponential model (1)
- external fixation (1)
- fibrosis imaging (1)
- fibrotest (1)
- flow cytometry (1)
- fracture (1)
- hadron spectroscopy (1)
- hadronic events (1)
- haemophilia A (1)
- head-and-neck cancer (1)
- heavy ion experiments (1)
- heavy-ion storage rings (1)
- helicity amplitude analysis (1)
- hemodynamic instability (1)
- hemorrhage (1)
- hepatitis C (1)
- high-risk neuroblastoma (1)
- immune reconstitution (1)
- inclusive J/ψ decays (1)
- induced membrane (1)
- interoperability (1)
- intrinsically disordered region (1)
- inverse kinematics (1)
- lactate (1)
- lapatinib (1)
- learning loss (1)
- lung cancer (1)
- mTOR inhibitor (1)
- management (1)
- membrane proteins (1)
- metastasis (1)
- metastatic prostate cancer (1)
- mindfulness (1)
- molecular machines (1)
- molecular tug-of-war (1)
- mortality (1)
- myocardial fibrosis (1)
- neoadjuvant therapy (1)
- neutron-induced reactions (1)
- non-ST-segment elevation acute coronary syndrome (1)
- non-invasive fibrosis assessment (1)
- nonstructural proteins (1)
- non‐selective beta‐blocker (1)
- nuclear cardiology (1)
- number of J/ψ events (1)
- oxLDL (1)
- p53 pathway (1)
- pIOL (1)
- pelvic injury (1)
- pelvic ring fracture (1)
- peptide editing (1)
- peptide-loading complex (1)
- photoacid (1)
- phylogeny (1)
- plasma-derived factor VIII concentrate, prophylaxis (1)
- point shear wave elastography (1)
- portal hypertension (1)
- primary active transporters (1)
- primary immunodeficiency (PID) (1)
- proteomics (1)
- proton transfer (1)
- pseudoexfoliative syndrome (1)
- psychotherapy process (1)
- quality control (1)
- quark gluon plasma (1)
- randomized controlled trial (RCT) (1)
- registry for primary immunodeficiency (1)
- resectability (1)
- risk group (1)
- scaffold size (1)
- scar (1)
- school closure (1)
- seed and soil (1)
- sequence alignment (1)
- smart home (1)
- smart living (1)
- spectra (1)
- sphingolipid (1)
- spinal bone metastasis (1)
- spine (1)
- spiro compounds (1)
- stage migration (1)
- structural biology (1)
- structural proteins (1)
- student achievement (1)
- surrogate reactions (1)
- survival (1)
- systematic review (1)
- tapasin (1)
- tetraquark (1)
- therapeutic alliance (1)
- traffic accident (1)
- transient elastography (1)
- transportation (1)
- trastuzumab (1)
- traumatic brain injury (1)
- trigger efficiency (1)
- ultrafast spectroscopy (1)
- vertebroplasty (1)
- web of things (1)
- x-ray techniques (1)
- Λ+c baryon (1)
- Σ hyperon (1)
- ψ(3686) (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1303)
- Frankfurt Institute for Advanced Studies (FIAS) (957)
- Informatik (922)
- Medizin (104)
- ELEMENTS (18)
- Geowissenschaften (10)
- Biochemie und Chemie (5)
- Exzellenzcluster Herz-Lungen-System (3)
- Informatik und Mathematik (3)
- Biochemie, Chemie und Pharmazie (2)
Background: Ribavirin (RBV) remains part of several interferon-free treatment strategies even though its mechanisms of action are still not fully understood. One hypothesis is that RBV increases responsiveness to type I interferons. Pegylated Interferon alpha (PEG-IFNa) has recently been shown to alter natural killer (NK) cell function possibly contributing to control of hepatitis C virus (HCV) infection. However, the effects of ribavirin alone or in combination with IFNa on NK cells are unknown.
Methods: Extensive ex vivo phenotyping and functional analysis of NK cells from hepatitis C patients was performed during antiviral therapy. Patients were treated for 6 weeks with RBV monotherapy (n = 11), placebo (n = 13) or PEG-IFNa-2a alone (n = 6) followed by PEG-IFNa/RBV combination therapy. The effects of RBV and PEG-IFNa-2a on NK cells were also studied in vitro after co-culture with K562 or Huh7.5 cells.
Results: Ribavirin monotherapy had no obvious effects on NK cell phenotype or function, neither ex vivo in patients nor in vitro. In contrast, PEG-IFNa-2a therapy was associated with an increase of CD56bright cells and distinct changes in expression profiles leading to an activated NK cell phenotype, increased functionality and decline of terminally differentiated NK cells. Ribavirin combination therapy reduced some of the IFN effects. An activated NK cell phenotype during therapy was inversely correlated with HCV viral load.
Conclusions: PEG-IFNa activates NK cells possibly contributing to virological responses independently of RBV. The role of NK cells during future IFN-free combination therapies including RBV remains to be determined.
Background & Aims: Phosphodiesterase‐5 inhibitors (PDE‐5‐I) are used for treatment of erectile dysfunction (ED), which is common in patients with cirrhosis. They may improve portal hypertension (PH), but contradictory data on efficacy and side‐effects have been reported. Non‐selective beta blockers (NSBB) reduce portal pressure, but might aggravate ED. Thus, we evaluated the combination of PDE‐5‐I with NSBB and its impact on PH and ED in experimental cirrhosis.
Methods: ED was assessed in cirrhotic patients (n = 86) using standardized questionnaire. Experimental cirrhosis was induced by bile‐duct‐ligation or carbon‐tetrachloride intoxication in rats. Corpus cavernosum pressure – a surrogate of ED ‐, as well as systemic and portal haemodynamics, were measured in vivo and in situ after acute administration of udenafil alone or in combination with propranolol. mRNA and protein levels of PDE‐5 signalling were analysed using PCR and western Blot.
Results: ED in humans was related to severity of liver disease and to NSBB treatment. PDE‐5 was mainly expressed in hepatic stellate cells and upregulated in human and experimental cirrhosis. Propranolol reduced corpus cavernosum pressure in cirrhotic rats and it was restored by udenafil. Even though udenafil treatment improved PH, it led to a reduction of mean arterial pressure. The combination of udenafil and propranolol reduced portal pressure and hepatic resistance without systemic side‐effects.
Conclusions: ED is common with advanced cirrhosis and concomitant NSBB treatment. The combination of PDE‐5‐I and NSBB improves ED and PH in experimental cirrhosis.
Acute deterioration of liver cirrhosis (e.g., infections, acute‐on‐chronic liver failure [ACLF]) requires an increase in cardiac contractility. The insufficiency to respond to these situations could be deleterious. Left ventricular global longitudinal strain (LV‐GLS) has been shown to reflect left cardiac contractility in cirrhosis better than other parameters and might bear prognostic value. Therefore, this retrospective study investigated the role of LV‐GLS in the outcome after transjugular intrahepatic portosystemic shunt (TIPS) and the development of ACLF. We included 114 patients (48 female patients) from the Noninvasive Evaluation Program for TIPS and Their Follow‐Up Network (NEPTUN) cohort. This number provided sufficient quality and structured follow‐up with the possibility of calculating major scores (Child, Model for End‐Stage Liver Disease [MELD], Chronic Liver Failure Consortium acute decompensation [CLIF‐C AD] scores) and recording of the events (development of decompensation episode and ACLF). We analyzed the association of LV‐GLS with overall mortality and development of ACLF in patients with TIPS. LV‐GLS was independently associated with overall mortality (hazard ratio [HR], 1.123; 95% confidence interval [CI],1.010‐1.250) together with aspartate aminotransferase (HR, 1.009; 95% CI, 1.004‐1.014) and CLIF‐C AD score (HR, 1.080; 95% CI, 1.018‐1.137). Area under the receiver operating characteristic curve (AUROC) analysis for LV‐GLS for overall survival showed higher area under the curve (AUC) than MELD and CLIF‐C AD scores (AUC, 0.688 versus 0.646 and 0.573, respectively). The best AUROC‐determined LV‐GLS cutoff was −16.6% to identify patients with a significantly worse outcome after TIPS at 3 months, 6 months, and overall. LV‐GLS was independently associated with development of ACLF (HR, 1.613; 95% CI, 1.025‐2.540) together with a MELD score above 15 (HR, 2.222; 95% CI, 1.400‐3.528). Conclusion: LV‐GLS is useful for identifying patients at risk of developing ACLF and a worse outcome after TIPS. Although validation is required, this tool might help to stratify risk in patients receiving TIPS.
Objectives: We explore the importance of SARS-CoV-2 sentinel surveillance testing in primary care during a regional COVID-19 outbreak in Austria.
Design: Prospective cohort study.
Setting: A single sentinel practice serving 22 829 people in the ski-resort of Schladming-Dachstein.
Participants: All 73 patients presenting with mild-to-moderate flu-like symptoms between 24 February and 03 April, 2020.
Intervention: Nasopharyngeal sampling to detect SARS-CoV-2 using real-time reverse transcriptase-quantitative PCR (RT-qPCR).
Outcome measures: We compared RT-qPCR at presentation with confirmed antibody status. We split the outbreak in two parts, by halving the period from the first to the last case, to characterise three cohorts of patients with confirmed infection: early acute (RT-qPCR reactive) in the first half; and late acute (reactive) and late convalescent (non-reactive) in the second half. For each cohort, we report the number of cases detected, the accuracy of RT-qPCR, the duration and variety of symptoms, and the number of viral clades present.
Results: Twenty-two patients were diagnosed with COVID-19 (eight early acute, seven late acute and seven late convalescent), 44 patients tested SARS-CoV-2 negative and 7 were excluded. The sensitivity of RT-qPCR was 100% among all acute cases, dropping to 68.1% when including convalescent. Test specificity was 100%. Mean duration of symptoms for each group were 2 days (range 1–4) among early acute, 4.4 days (1–7) among late acute and 8 days (2–12) among late convalescent. Confirmed infection was associated with loss of taste. Acute infection was associated with loss of taste, nausea/vomiting, breathlessness, sore throat and myalgia; but not anosmia, fever or cough. Transmission clusters of three viral clades (G, GR and L) were identified.
Conclusions: RT-qPCR testing in primary care can rapidly and accurately detect SARS-CoV-2 among people with flu-like illness in a heterogeneous viral outbreak. Targeted testing in primary care can support national sentinel surveillance of COVID-19.
Activation of Mitochondrial complex II-dependent respiration is beneficial for α-Synucleinopathies
(2015)
Parkinson’s disease and dementia with Lewy bodies are major challenges in research and clinical medicine world-wide and contribute to the most common neurodegenerative disorders. Previously, specific mitochondrial polymorphisms have been found to enhance clearance of amyloid-β from the brain of APP-transgenic mice leading to beneficial clinical outcome. It has been discussed whether specific mitochondrial alterations contribute to disease progression or even prevent toxic peptide deposition, as seen in many neurodegenerative diseases. Here, we investigated α-synuclein-transgenic C57BL/6J mice with the A30P mutation, and a novel A30P C57BL/6J mouse model with three mitochondrial DNA polymorphisms in the ND3, COX3 and mtRNAArg genes, as found in the inbred NOD/LtJ mouse strain. We were able to detect that the new model has increased mitochondrial complex II-respiration which occurs in parallel to neuronal loss and improved motor performance, although it exhibits higher amounts of high molecular weight species of α-synuclein. High molecular weight aggregates of different peptides are controversially discussed in the light of neurodegeneration. A favourable hypothesis states that high molecular weight species are protective and of minor importance for the pathogenesis of neurodegenerative disorders as compared to the extreme neurotoxic monomers and oligomers. Summarising, our results point to a potentially protective and beneficial effect of specific mitochondrial polymorphisms which cause improved mitochondrial complex II-respiration in α-synucleinopathies, an effect that could be exploited further for pharmaceutical interventions.
Aims: Patients with cardiovascular comorbidities have a significantly increased risk for a critical course of COVID-19. As the SARS-CoV2 virus enters cells via the angiotensin-converting enzyme receptor II (ACE2), drugs which interact with the renin angiotensin aldosterone system (RAAS) were suspected to influence disease severity.
Methods and results: We analyzed 1946 consecutive patients with cardiovascular comorbidities or hypertension enrolled in one of the largest European COVID-19 registries, the Lean European Open Survey on SARS-CoV-2 (LEOSS) registry. Here, we show that angiotensin II receptor blocker intake is associated with decreased mortality in patients with COVID-19 [OR 0.75 (95% CI 0,59–0.96; p = 0.013)]. This effect was mainly driven by patients, who presented in an early phase of COVID-19 at baseline [OR 0,64 (95% CI 0,43–0,96; p = 0.029)]. Kaplan-Meier analysis revealed a significantly lower incidence of death in patients on an angiotensin receptor blocker (ARB) (n = 33/318;10,4%) compared to patients using an angiotensin-converting enzyme inhibitor (ACEi) (n = 60/348;17,2%) or patients who received neither an ACE-inhibitor nor an ARB at baseline in the uncomplicated phase (n = 90/466; 19,3%; p<0.034). Patients taking an ARB were significantly less frequently reaching the mortality predicting threshold for leukocytes (p<0.001), neutrophils (p = 0.002) and the inflammatory markers CRP (p = 0.021), procalcitonin (p = 0.001) and IL-6 (p = 0.049). ACE2 expression levels in human lung samples were not altered in patients taking RAAS modulators.
Conclusion: These data suggest a beneficial effect of ARBs on disease severity in patients with cardiovascular comorbidities and COVID-19, which is linked to dampened systemic inflammatory activity.
SARS-CoV-2 and stroke characteristics: a report from the Multinational COVID-19 Stroke Study Group
(2020)
Background: Stroke is reported as a consequence of SARS-CoV-2 infection. However, there is a lack of regarding comprehensive stroke phenotype and characteristics
Methods: We conducted a multinational observational study on features of consecutive acute ischemic stroke (AIS), intracranial hemorrhage (ICH), and cerebral venous or sinus thrombosis (CVST) among SARS-CoV-2 infected patients. We further investigated the association of demographics, clinical data, geographical regions, and countries’ health expenditure among AIS patients with the risk of large vessel occlusion (LVO), stroke severity as measured by National Institute of Health stroke scale (NIHSS), and stroke subtype as measured by the TOAST criteria. Additionally, we applied unsupervised machine learning algorithms to uncover possible similarities among stroke patients.
Results: Among the 136 tertiary centers of 32 countries who participated in this study, 71 centers from 17 countries had at least one eligible stroke patient. Out of 432 patients included, 323(74.8%) had AIS, 91(21.1%) ICH, and 18(4.2%) CVST. Among 23 patients with subarachnoid hemorrhage, 16(69.5%) had no evidence of aneurysm. A total of 183(42.4%) patients were women, 104(24.1%) patients were younger than 55 years, and 105(24.4%) patients had no identifiable vascular risk factors. Among 380 patients who had known interval onset of the SARS-CoV-2 and stroke, 144(37.8%) presented to the hospital with chief complaints of stroke-related symptoms, with asymptomatic or undiagnosed SARS-CoV-2 infection. Among AIS patients 44.5% had LVO; 10% had small artery occlusion according to the TOAST criteria. We observed a lower median NIHSS (8[3-17], versus 11 [5-17]; p=0.02) and higher rate of mechanical thrombectomy (12.4% versus 2%; p<0.001) in countries with middle to high-health expenditure when compared to countries with lower health expenditure. The unsupervised machine learning identified 4 subgroups, with a relatively large group with no or limited comorbidities.
Conclusions: We observed a relatively high number of young, and asymptomatic SARS-CoV-2 infections among stroke patients. Traditional vascular risk factors were absent among a relatively large cohort of patients. Among hospitalized patients, the stroke severity was lower and rate of mechanical thrombectomy was higher among countries with middle to high-health expenditure.
Stratospheric inorganic chlorine (Cly) is predominantly released from long-lived chlorinated source gases and, to a small extent, very short-lived chlorinated substances. Cly includes the reservoir species (HCl and ClONO2) and active chlorine species (i.e., ClOx). The active chlorine species drive catalytic cycles that deplete ozone in the polar winter stratosphere. This work presents calculations of inorganic chlorine (Cly) derived from chlorinated source gas measurements on board the High Altitude and Long Range Research Aircraft (HALO) during the Southern Hemisphere Transport, Dynamic and Chemistry (SouthTRAC) campaign in austral late winter and early spring 2019. Results are compared to Cly in the Northern Hemisphere derived from measurements of the POLSTRACC-GW-LCYCLE-SALSA (PGS) campaign in the Arctic winter of 2015/2016. A scaled correlation was used for PGS data, since not all source gases were measured. Using the SouthTRAC data, Cly from a scaled correlation was compared to directly determined Cly and agreed well. An air mass classification based on in situ N2O measurements allocates the measurements to the vortex, the vortex boundary region, and midlatitudes. Although the Antarctic vortex was weakened in 2019 compared to previous years, Cly reached 1687±19 ppt at 385 K; therefore, up to around 50 % of total chlorine was found in inorganic form inside the Antarctic vortex, whereas only 15 % of total chlorine was found in inorganic form in the southern midlatitudes. In contrast, only 40 % of total chlorine was found in inorganic form in the Arctic vortex during PGS, and roughly 20 % was found in inorganic form in the northern midlatitudes. Differences inside the two vortices reach as much as 540 ppt, with more Cly in the Antarctic vortex in 2019 than in the Arctic vortex in 2016 (at comparable distance to the local tropopause). To our knowledge, this is the first comparison of inorganic chlorine within the Antarctic and Arctic polar vortices. Based on the results of these two campaigns, the differences in Cly inside the two vortices are substantial and larger than the inter-annual variations previously reported for the Antarctic.
Introduction: Prophylaxis with factor VIII (FVIII) concentrates in children with haemophilia A (HA) is current standard of care. The benefit of prophylactic treatment for adult HA patients is not commonly accepted.
Aim: To investigate the benefit of prophylaxis over on‐demand treatment in adult and elderly patients with severe or non‐severe HA in a real‐life setting.
Methods: Data from 163 patients comprising 1202 patient‐years were evaluated for 7.5 (±5.3) years. The effects on the annual bleeding rate (ABR, including spontaneous and traumatic bleeds) of treatment with a plasma‐derived FVIII concentrate, the patient's age and disease severity were investigated. The effect of changing the treatment from on demand to continuous prophylaxis on the patients’ ABRs was further analysed.
Results: Prophylaxis had the greatest effect on the ABRs of patients of any age with severe or non‐severe HA. The difference in ABR of all patients treated on demand (median 31.4; interquartile range (IQR) 27.6; N = 83) compared with those treated prophylactically (median 1.3; IQR 3.6; N = 122) was statistically significant (P < .05), even for patients with non‐severe HA (median 8.4; IQR 15.5; N = 11) vs median 1.5; IQR 4.2 (N = 17), P < .05). Patients, aged up to 88 years, switching from on demand to continuous prophylaxis showed the lowest median ABR (1.1; N = 51) after their regimen change.
Conclusion: Any (even low‐frequency) prophylaxis results in lower ABR than on‐demand treatment. Patients switching to prophylaxis benefitted the most, irrespective of age or HA severity. Prophylactic treatment—even tertiary—is the regimen of choice for patients of any age, including elderly patients, with severe or non‐severe HA.
Improved integration of single cell transcriptome data demonstrated on heart failure in mice and men
(2023)
Biomedical research frequently uses murine models to study disease mechanisms. However, the translation of these findings to human disease remains a significant challenge. In order to improve the comparability of mouse and human data, we present a cross-species integration pipeline for single-cell transcriptomic assays.
The pipeline merges expression matrices and assigns clear orthologous relationships. Starting from Ensembl ortholog assignments, we allocated 82% of mouse genes to unique orthologs by using additional publicly available resources such as Uniprot, and NCBI databases. For genes with multiple matches, we employed the Needleman-Wunsch global alignment based on either amino acid or nucleotide sequence to identify the ortholog with the highest degree of similarity.
The workflow was tested for its functionality and efficiency by integrating scRNA-seq datasets from heart failure patients with the corresponding mouse model. We were able to assign unique human orthologs to up to 80% of the mouse genes, utilizing the known 17,492 orthologous pairs. Curiously, the integration process enabled the identification of both common and unique regulatory pathways between species in heart failure.
In conclusion, our pipeline streamlines the integration process, enhances gene nomenclature alignment and simplifies the translation of mouse models to human disease. We have made the OrthoIntegrate R-package accessible on GitHub (https://github.com/MarianoRuzJurado/OrthoIntegrate), which includes the assignment of ortholog definitions for human and mouse, as well as the pipeline for integrating single cells.